NCT06144697View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants

PHASE1TerminatedINTERVENTIONAL
Enrollment

267

Participants

Timeline

Start Date

January 29, 2024

Primary Completion Date

October 16, 2024

Study Completion Date

October 16, 2024

Conditions
Healthy Participants
Interventions
DRUG

BMS-986465

Specified dose on specified days

OTHER

Placebo

Specified dose on specified days

DRUG

Pegasys

Specified dose on specified days

DRUG

Famotidine

Specified dose on specified days

Trial Locations (2)

78744

Local Institution - 0003, Austin

92801

Local Institution - 0001, Anaheim

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY